Skip to main content

Page last checked

Glucagon/GLP-1 dual receptor agonist (investigational) · safety

Survodutide side effects

The survodutide side effects reported most often are stomach and gut events overall, nausea and vomiting. The full list is below, with the cited trial report cited at the bottom of the page.

These effects tend to cluster at the start and after each dose increase, and to settle down while the dose stays the same.

Survodutide is an experimental weekly injection being studied for weight loss and a liver disease called MASH. It acts on GLP-1 and glucagon signals. Sellers offer unapproved survodutide to people seeking weight loss.

A phase 2 trial reported average weight loss over 46 weeks. Larger phase 3 trials are underway, and survodutide does not have FDA approval.

Further down: the full list with frequencies · when to get medical help · questions

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewerReviewed 2026-08-20open the primary sources

At a glance

Common reactions listed

4

Serious reactions listed

0

Boxed warning

No label exists

Strongest source

Human trial

The counts show how many distinct reactions the cited trial report names. The percentages show how often a reaction appeared in a study group, not the chance that it will happen to you.

Common reactions

The full list, as reported across the available trial evidence. There is no approved label to read frequency bands off, so these are the trials’ own figures.

◆ Common reactionstrial-reported
ReactionFrequency
Stomach and gut events overall (nausea, vomiting, constipation)Reported in 75% of survodutide recipients (vs 42% placebo)
NauseaReported in trials (dose-dependent)
VomitingReported in trials (dose-dependent)
Any adverse eventReported in 91% of survodutide recipients (vs 75% placebo), mostly stomach and gut events

Human trialEvery reaction above comes from a cited trial. These are study findings, not instructions on what to take.

When to seek medical care

The trial report does not give a separate list of serious reactions. There is also no approved label. That gap does not mean serious reactions cannot happen. This compound has been studied in fewer people and for less time than an approved drug.

EmergencySome symptoms should not wait for an appointment. Call emergency services (911 in the US) if they are severe, getting worse fast, or involve trouble breathing, chest pain, fainting or confusion.

1Read deeperTiming, evidence limits, and product context

What the 46-week trial can—and cannot—show

The page above comes from a dose-finding study with 387 people. It tested weekly doses of 0.6 mg · 2.4 mg · 3.6 mg · 4.8 mg. The study shows what happened during that window. It may miss rare or later problems.

This page preserves 4 common reactions and 0 serious entries from that report. A missing reaction is outside this bounded record; it is not a result that the reaction cannot occur.

  • Investigational compound — no approved dosing exists
  • Trial doses are study information, not a recommendation
  • Trial escalation ran up to 20 weeks — rapid dose increases were not studied

FDA has not approved survodutide, also called BI 456906.

Phase 3 SYNCHRONIZE trials study obesity. A separate phase 2 program studies MASH, a form of liver disease. No dosing label exists, and any product sold today is unapproved.

The doses here describe study groups, not advice.

Common questions

How long do survodutide side effects last, and do they go away?

The 46-week trial report does not establish a set number of days for any reaction. It records whether an event occurred during the study, not a reliable personal countdown for when it will stop.

What are the most common survodutide side effects?

Stomach and gut events overall (nausea, vomiting, constipation), nausea, vomiting and any adverse event — the table above has the rest, each with its frequency band and source.

Does survodutide have a boxed warning?

No, because a boxed warning is part of an FDA-approved label and survodutide has no approved label. That reflects what regulatory review has and has not covered, not a finding that serious risks were looked for and ruled out.

Can the survodutide dose be lowered if side effects are hard to tolerate?

That decision belongs to the prescribing clinician. No approved schedule exists for this compound, so there is no labeled framework for adjusting a dose. That leaves the prescriber as the only place the decision can sit.

Were hair loss, fatigue or constipation listed for survodutide?

In the 46-week report, constipation was listed; hair loss and fatigue were not. That is a statement about the paper’s recorded terms, not proof that an unlisted symptom cannot occur.

What should someone do about a serious survodutide reaction?

Contact a clinician promptly, and emergency services if symptoms are severe or getting worse quickly. The available sources do not list any reactions as separately serious. That means there is no early-warning list here—not that serious reactions are impossible.

Do the frequencies on this page mean the chance it happens to one person?

No. These figures describe groups in a study. A band shows how often a reaction appeared under that trial’s conditions. It cannot predict what will happen to one person.

Related

The schedule these reactions were recorded against, the comparisons, and the sourcing rules behind every grade on this page.

What survodutide is, how it is used, and what has been studied

Survodutide is a glucagon/glp-1 dual receptor agonist (investigational).

How the survodutide trials escalated to their top arm

The strongest dose source for survodutide is a published human trial.

Survodutide concentration and dose-draw tool

The concentration in mg/mL for every survodutide vial and water pairing, printed in full.

The survodutide half of survodutide vs tirzepatide

Each page in survodutide vs tirzepatide on its own terms, rather than folded into survodutide.

Take the survodutide arithmetic to any other vial

Concentration, units per draw and draws per vial, including Survodutide

Which other pages list constipation besides survodutide

One reaction, constipation, read down every page instead of out of survodutide alone.

Which other pages list nausea besides survodutide

One reaction, nausea, read down every page instead of out of survodutide alone.

Survodutide in the regulatory changelog

A proceeding with no published outcome is entered as exactly that, including survodutide

Questions readers ask

Is survodutide safe?

Nobody can say yet — it is investigational, and the published picture is one 387-person trial. In it 91% of survodutide recipients recorded some unwanted event against 75% on placebo, and gut events hit 75% against 42%.

That trial ran 46 weeks, with up to 20 weeks of stepping the dose up. A phase 2 trial maps dose against response; it is not big enough to catch uncommon harm.

Which GLP-1 has the worst side effects?

No trial has ranked them, and the numbers on these pages cannot be lined up to do it. Each comes from a separate trial with different participants, different endpoints and a different ramp-up.

Only one head-to-head between two of these drugs appears in this registry. That one set semaglutide against tirzepatide, and measured weight and waist size. Survodutide has no published head-to-head against anything.

What is the difference between survodutide and tirzepatide?

Different second receptor, and a different regulatory position. Survodutide pairs GLP-1 with glucagon — one signal cuts what you take in, the other raises what you burn.

Tirzepatide pairs GLP-1 with GIP, the other gut hormone released after eating, and it has an FDA-approved label. Survodutide has none: it sits in phase 3 as the SYNCHRONIZE program, with a separate phase 2 program in fatty-liver disease.

What happens when you stop taking GLP-1?

This page follows nobody after they stopped, so it cannot answer. The phase 2 trial measured 46 weeks on the drug: −6.2% to −14.9% mean weight change across the arms, against −2.8% on placebo.

No approved label exists for this compound, and a label is where a stopping rule would live. Anything circulating about what follows a stop is not coming from this trial.

1primary source, each with the day we read it — open the documents used on this page